Novo still expecting EU Wegovy approval around the New Year
Before the turn of the year, Novo Nordisk predicts it will have received marketing approval for its obesity drug Wegovy in Europe.
by marketwire, translated by daniel pedersen
There is still hope that obesity treatment Wegovy will be authorized for the European market before the end of the year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
